HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3)

The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials. 

Studies to be supported by this FOA may include those necessary for the identification and initial biological, analytical, and clinical validation of pain biomarkers or biomarker signatures, and must include human samples and data as the source for candidate biomarkers or signatures identification and development if possible. If not, biomarkers or signatures resulting from identification in animal models must be verified in human samples at the end of the UG3 phase or during the UH3 phase.

Funding: UG3 $500,000 per year; UH3 $1,500,000 per year 

Duration: 5 years

Research Authority due date: 10 days prior to submission. 

LOI (encouraged) due dates: 10.5.23, 23.9.23

Full application due dates: 10.6.23, 23.10.23